Phase 2 Recurrent Mantle Cell Lymphoma Clinical Trials
6 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–6 of 6 trials
Recruiting
Phase 2
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Chronic Lymphocytic LeukemiaMantle Cell LymphomaRecurrent Chronic Lymphocytic Leukemia+6 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT06839053
Recruiting
Phase 2
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
National Cancer Institute (NCI)20 enrolled5 locationsNCT07003295
Recruiting
Phase 2
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center80 enrolled1 locationNCT04054167
Recruiting
Phase 2
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
City of Hope Medical Center36 enrolled1 locationNCT04484012
Recruiting
Phase 2
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Recurrent Follicular LymphomaRefractory Follicular LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+8 more
University of Washington40 enrolled1 locationNCT05453396
Recruiting
Phase 2
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Academic and Community Cancer Research United100 enrolled2 locationsNCT05910801